US equities
|
NVDA
$166.19
▼-4.34%
AMD
$585.30
▲+5.86%
MU
$798.44
▼-1.59%
AVGO
$364.36
▲+5.54%
SPCX
$139.94
▲+0.14%
SNDK
$937.46
▼-4.11%
TSLA
$397.45
▲+1.69%
AAPL
$354.88
▼-0.21%
NVDA
$166.19
▼-4.34%
AMD
$585.30
▲+5.86%
MU
$798.44
▼-1.59%
AVGO
$364.36
▲+5.54%
SPCX
$139.94
▲+0.14%
SNDK
$937.46
▼-4.11%
TSLA
$397.45
▲+1.69%
AAPL
$354.88
▼-0.21%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Tools
My watchlist
My portfolio
Recent quotes
Mesoblast Limited - American Depositary Shares
(NQ:
MESO
)
13.10
-0.55 (-4.03%)
Delayed Quote
Updated: 4:00 PM EST, Nov 12, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Mesoblast Limited - American Depositary Shares
The $45 Billion Cell Therapy Boom Just Hit a Manufacturing Milestone Most Investors Haven’t Noticed
March 18, 2026
AVAI, FBLG, FATE, MESO, and LGVN as Regenerative Medicine Moves From Lab to GMP Manufacturing Facilities
From
USA News Group
Via
GlobeNewswire
Mesoblast Ltd. (NASDAQ: MESO) Near the Top of Equities by Percentage Gain on 4/1
April 01, 2024
Via
Investor Brand Network
Reddit Inc. (NYSE: RDDT) Surges, Uncovering Undervalued Opportunities: DYAI, INBS, MESO, VTAK
March 28, 2024
Via
AB Newswire
Topics
Initial Public Offering
Mesoblast Ltd. (NASDAQ: MESO) is One of Tuesday Morning’s Most Active Stocks
March 26, 2024
Via
Investor Brand Network
A Look At Some Of The Companies Innovating In the Cutting-Edge Regenerative Medicine Field
October 14, 2022
Biotechnology companies have broken many medical barriers in the past 40 years, harnessing the technological revolution to bring innovative solutions to medical problems.
Via
TheNewswire.com
R&D Efforts for Alzheimer’s Therapies on the Rise with over 120 Drugs in Development
March 31, 2022
Palm Beach, FL – March 31, 2022 – FinancialNewsMedia.com News Commentary – Alzheimer’s disease (AD) is an irreversible, progressive neurodegenerative disease. It is the most common cause of dementia...
Via
FinancialNewsMedia
Alzheimer’s Disease Expected to Triple by 2050 While the Development Process for Potential Drug Candidates Increases
January 05, 2022
Palm Beach, FL – January 5, 2022 – FinancialNewsMedia.com News Commentary – Alzheimer’s disease (AD) is the most common reason of progressive dementia in the elderly population. There has been an...
Via
FinancialNewsMedia
Topics
Death